[Inhibited proliferation and expression of human nasopharyngeal carcinoma line induced by celecoxib in vitro].
OBJECTIVE
To study the effects of celecoxib on the cell proliferation and expression of vascular endothelial growth factor (VEGF) in human nasopharyngeal carcinoma line.


METHODS
3-[ 4,5-dimethylthiazol-2-yl]-2, 5-diphenyl tetrazolium bromide (MTT) test was used to investigate the cell proliferation. Flow cytometry (FCM) was used to analyze the cell cycle arrest. Immunocytochemistry technique was to observe the expression of VEGF.


RESULTS
Celecoxib inhibited the growth of nasopharyngeal carcinoma line, the cell number of G0/G1 phase increased from 62.13% to 91.35%, and the cell number of G2/M and S phase decreased from 21.59% to 3.56% and from 16.28% to 5.01%, respectively, cell cycle progression was arrested at G1/S phase. Celecoxib decreased the positive expression of VEGF in HNE-1 cells.


CONCLUSIONS
Celecoxib inhibited the proliferation of nasopharyngeal carcinoma significantly and the expression of VEGF.
Jiang
Dai-Hua
DH
Department of Otorhinolaryngology, The 161 Center Hospital of People's Liberation Army, Wuhan 430010, China.
Guo
De-Yu
DY
Li
Hao-Zhun
HZ
Deng
Wei
W
D000068579:Celecoxib; D045744:Cell Line, Tumor / Q000187:drug effects / Q000378:metabolism; D049109:Cell Proliferation / Q000187:drug effects*; D006801:Humans; D009303:Nasopharyngeal Neoplasms / Q000378:metabolism / Q000473:pathology; D011720:Pyrazoles / Q000494:pharmacology*; D013449:Sulfonamides / Q000494:pharmacology*; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism*
D011720:Pyrazoles; D013449:Sulfonamides; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068579:Celecoxib